louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02074098: Endotracheal Intubation Using Macintosh Laryngoscope, Glidescope, Airwayscope During Chest Compression With Adjustment Height of a Bed
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Tracheal Intubation
Cardiac Arrest
Keywords: intubation
Cardiopulmonary resuscitation
Manikin study
Lead sponsor: Hanyang University
Sponsor class: OTHER
First posted: 2014-02-28
Enrollment: 21
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to determine whether a bed height make an effect to endotracheal intubation with Macintosh laryngoscope, Glidescope and Airwayscope during chest compressions in- hospital simulation cardiac arrest.


Eligibility criteria: Inclusion Criteria:

* Experience of Intubation \> 50 times
* Postgraduates year 1,2,3,4 and Emergency physicians in emergency department

Exclusion Criteria:

* Wrist or low back disease

Primary outcomes:
measure: To measure a time to expose the glottis view with a laryngoscope
timeFrame: 1 day
measure: To measure a time to intubate the tube with a laryngoscope
timeFrame: 1 day
measure: To estimate the success rate of Intubation
timeFrame: 1 day
Secondary outcomes:
measure: To assess the grade for the glottis view with a laryngoscopy
timeFrame: 1 day
Other outcomes:
measure: To assess the preference for a type of laryngoscopes
timeFrame: 1 day
Locations:
city: Seoul
country: Korea, Republic of
facility: Hanyang University Seoul Hospital
Study officials:
References:
Clinical trial NCT06196398: Effects of Medical Treatment of ICAS With Hemodynamic Disorders Based on MR-FFR
Official title: Effects of Medical Treatment of Intracranial Atherosclerotic Diseases Based on Magnetic Resonance Fractional Flow Reserve
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Stroke, Ischemic
Intracranial Atherosclerosis
Keywords: Intracranial atherosclerotic diseases
Fractional Flow Reserve
Hemodynamics
Stroke
Lead sponsor: Xuanwu Hospital, Beijing
Sponsor class: OTHER
Collaborators: name: National Key Research and Development Project, China
First posted: 2024-01-09
Enrollment: 400
Sex: ALL
Minimum age (years): 30
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with symptomatic, moderate to severe stenosis of major arteries in intracranial anterior circulation. The stenosis degree is ≥ 50%, confirmed by imaging evidence, according to modified WASID criteria.

Brief summary: This multicenter prospective cohort study aims to compare the difference in the effects of medical treatment within 1 year between the two groups of ICAS patients divided hemodynamically by Magnetic Resonance Fractional Flow Reserve. PC MRA will be applied for FFR measurement. The primary outcome is the composite of ischemic stroke or death related to the qualifying artery territory for 1 year.


Eligibility criteria: Inclusion Criteria:

1. Patients aged from 30 to 80 with symptomatic ICAS lesion in anterior circulation.
2. 50% to 99% stenosis (in accordance with modified WASID method) confirmed by DSA, CTA or MRA.
3. mRS 0-2 points
4. Informed of the study protocol and objectives.

Exclusion Criteria:

1. Previous endovascular treatment or surgery for cerebrovascular diseases
2. Large cerebral infarction (more than 1/2 MCA perfusion area) according to MRI
3. Combined with other neurological diseases, such as aneurysm, arteriovenous malformation, tumor, hydrocephalus, cerebral trauma, cerebral hemorrhage, multiple sclerosis, epilepsy and intracranial infection.
4. Pregnancy or in the preparation for pregnancy
5. Patients who cannot tolerate or do not allow MR screening, including metal implanting and claustrophobia
6. Contraindication for antiplatelet drugs or statins
7. Patients with severe dementia or mental disorders, who cannot cooperate with examination

Primary outcomes:
measure: The composite of ischemic stroke or death related to the qualifying artery territory
timeFrame: 1 year
Secondary outcomes:
measure: Functional evaluation
timeFrame: 1 year
Other outcomes:
Locations:
city: Beijing
country: China
facility: Xuanwu Hospital, Capital Medical University
state: Beijing
Study officials:
References:
Clinical trial NCT03305198: BIOlogical Response to Exercise : A Metabolomic Study in Peripheral Artery Disease (BIOR)
Official title: BIOlogical Response to Exercise : A Metabolomic Study in Peripheral Artery Disease (BIOR)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Peripheral Artery Disease
Lead sponsor: University Hospital, Angers
Sponsor class: OTHER_GOV
First posted: 2017-10-09
Enrollment: 69
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Analysis of changes in metabolomic signature from rest to post exercise
Primary purpose: BASIC_SCIENCE

Brief summary: The measurement of the transcutaneous oxygen pressure during walking allows to estimate the importance of ischemia, bilaterally and segment of limb by segment of limb. The determination of the metabolic compounds concentration, with metabolomic approach, is emerging in physiology and exercise.

This pilot study focuses on the feasibility of the metabolomics analysis with micro method , by capillary drawing from earlobe sampling, for patients with peripheral artery disease (PAD)

Detailed description: Ankle brachial index is measured at rest for alml subjects. Blood sample (180-360 microliter) will be collected at rest transcutaneous oxygen pressure is measured at the chest, calves and buttocks and results will be expressed as the minimal value of the DROP index (Limb changes minus chest changes) Patients walk on treadmill (2MPH 10% slope) until exertional limb pain. Blood sample (180 microliter) will be collected again, at minute 3 of recovery from walking Correlation of each metobolite increase to the sum of DROP values wil be studied.

Eligibility criteria: Inclusion Criteria:

* Age \> 18 years old
* Patient able to walk on a treadmill
* Patient agrees to be involve in the protocol and sign the consent form

Exclusion Criteria:

* Patient not covered by the French health insurance
* Patient has a wash-out period for another clinical trial
* Patient with comorbidity as bleeding disorder or with a anticoagulant therapy

Primary outcomes:
measure: Chances in the metabolomic signature of arterial claudication by capillary blood sampling from the earlobe
timeFrame: Half an hour (includes the resting walking and recovery period of exercise)
Secondary outcomes:
measure: Changes inthe correlation of observed metabolomic variations and the importance of ischemia evaluated by oximetry
timeFrame: Half an hour (includes the resting walking and recovery period of exercise)
Other outcomes:
Locations:
city: Angers
country: France
facility: Centre hospitalier universitaire
Study officials:
affiliation: University Hospital in Angers
name: Pierre ABRAHAM, MD, Ph.D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05283798: Insertion of Copper T380 Versus Multiload IUD Post Partum
Official title: Postpartum Intra-caesarean Section Insertion of Copper T380 Versus Multiload 375 IUD in a Randomized Controlled Trial.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: IUD
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2022-03-17
Enrollment: 300
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To compare efficacy safety \& side effects of multiload 375 IUD versus copper T 380 IUD when inserted during elective CS

Detailed description: Insertion of an intrauterine device (IUD) immediately after delivery is appealing for several reasons. The woman is known not to be pregnant, her motivation for contraception may be high, and the setting may be convenient for both the woman and her provider The World Health Organization (WHO) recommends that a woman should wait at least 24 months after delivery before the next pregnancy to decrease the adverse maternal, perinatal ,and infant outcomes.

Compared with other contraceptive methods, early post-partum IUD insertion has several advantages. It provides immediate contraception without interfering with breast feeding, and it may avoid discomfort related to insertion. Inserting an IUD immediately after placental removal has not been associated with increased infection, uterine perforation, postpartum bleeding, or uterine subinvolution . The expulsion rate is higher (approximately 12% in the first postpartum year) after immediate postpartum insertion compared to insertion 4 to 8 weeks later. Continuation rates are relatively high (87.6% and 76.3%, at 6 and 12 months, respectively Studies have shown that with effective provider training, the immediate postpartum IUD insertion (IPPIUD) complications such as expulsion, pelvic infection, bleeding, pain, missing threads ,and failure rates are not significantly different from those of interval PPIUD insertion (4:6 weeks) after delivery

Eligibility criteria: Inclusion Criteria:

women delivered by elective CS ≥ 36 wks

Exclusion Criteria:

Patients with PROM Patients on corticosteroids therapy Patients on anticoagulant patients who refuse participate in the study with written consent

Primary outcomes:
measure: expulsion rate after 6 weeks of insertion
timeFrame: 6 weeks
Secondary outcomes:
measure: compare bleedind dayes and shift to anthor methoud
timeFrame: 6 weeks
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03578198: Rituximab Plus MG4101 Indolent CD20-positive Non-Hodgkin Lymphoma (NHL)
Official title: Phase II Study of Rituximab Plus MG4101 in Patients With Relapsed or Refractory Indolent CD20-positive Non-Hodgkin Lymphoma (NHL)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: CD20-positive Non-Hodgkin Lymphoma
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
Collaborators: name: Hallym University Medical Center
name: Kyunghee University Medical Center
name: Gyeongsang National University Hospital
First posted: 2018-07-06
Enrollment: 12
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Phase II study of rituximab plus MG4101 in patients with relapsed or refractory indolent CD20-positive non-Hodgkin lymphoma (NHL) Investigator-Initiated Trials

Detailed description: Multi-center trial, Phase II, non-randomized, open-label, single-arm study with combined therapy of rituximab plus MG4101 in patients with indolent CD20-positive NHLs who has relapsed or refractory to prior chemotherapy or chemo-radiotherapy.

Eligibility criteria: Inclusion Criteria:

1. Histologically confirmed indolent CD20-positive NHLs (iNHLs; follicular lymphoma grade 1-3a, marginal zone B-cell lymphoma, small lymphocytic lymphoma, Waldenstrom macroglobulinemia)
2. CD20-positive iNHL patients who relapsed or progressed
3. ≥ 19 years
4. ECOG PS 0-2
5. At least one bidimensionally measurable disease (or presence of IgM paraproteinemia ≥ 2 x ULN for Waldenstrom macroglobulinemia)
6. Adequate hematologic, renal, and hepatic functions
7. Appropriate methods of contraception during the study
8. Written informed consent

Exclusion Criteria:

1. Not all of the above inclusion criteria are met.
2. Prior chemotherapy within 4 weeks or radiotherapy within 6 weeks
3. Corticosteroids \> 10mg/day during last 28 days
4. Evidence of CNS involvement by lymphomas
5. Active HBV/HCV infections, known HIV infection
6. Prior diagnosis of cancers within 5 years
7. Serious concurrent cardiovascular disease
8. Patients who are pregnant or lactating

Primary outcomes:
measure: Overall response rate
timeFrame: Through treatment completion, an average of 25 weeks
Secondary outcomes:
measure: Complete remission rate
timeFrame: Through treatment completion, an average of 25 weeks
measure: Progression-free survival
timeFrame: From date of initiation until the date of first documented progression, whichever came first, assessed up to 2 years
measure: Overall survival
timeFrame: Through study completion, an average of 2 years
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
affiliation: Seoul National University Hospital
name: Tae Min Kim, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04260698: Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
Official title: An Open Label Expanded Access Study of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE3
Conditions: Hematological Malignancies
Lead sponsor: Gamida Cell ltd
Sponsor class: INDUSTRY
First posted: 2020-02-07
Enrollment: 36
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Omidubicel is an investigational therapy for patients with high-risk hematologic malignancies.

Detailed description: Successful blood and marrow transplantation (BMT) requires the infusion of a sufficient number of hematopoietic stem/progenitor cells (HSPCs), capable of both homing to the bone marrow and regenerating a full array of hematopoietic cell lineages with early and late repopulating ability in a timely fashion.

Omidubicel is a stem/progenitor cell-based product composed of ex vivo expanded allogeneic cells from one entire unit of umbilical cord blood. Omidubicel utilizes the small molecule nicotinamide (NAM), as an epigenetic approach to inhibit differentiation and to increase the migration, bone marrow (BM) homing and engraftment efficiency of hematopoietic progenitor cells (HPC) expanded in ex vivo cultures.

The overall study objectives are to provide access to omidubicel for transplantation in patients with hematological malignancies and to collect additional safety and efficacy data.

Eligibility criteria: Inclusion Criteria:

* Patients must be at least 12 years of age
* Applicable disease criteria
* Patients must have one or two partially HLA-matched CBUs
* Back-up stem cell source
* Sufficient physiological reserves
* Females of childbearing potential agree to use appropriate method of contraception
* Signed written informed consent

Exclusion Criteria:

* Extensive bone marrow fibrosis
* Donor specific anti-HLA antibodies
* Pregnancy
* Medically unsuitable for transplant

Primary outcomes:
measure: To assess the time from transplant to neutrophil engraftment
timeFrame: by day 42 post-transplant inclusive
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: UCLA
state: California
city: Palo Alto
country: United States
facility: Stanford University Cancer Institute
state: California
city: Maywood
country: United States
facility: Loyola University, Cardinal Bernardin Cancer Center
state: Illinois
city: Minneapolis
country: United States
facility: University of Minnesota Masonic Cancer Center
state: Minnesota
city: Durham
country: United States
facility: Duke University Medical Center
state: North Carolina
city: Portland
country: United States
facility: Oregon Health & Science University
state: Oregon
Study officials:
affiliation: Duke University
name: Mitchell Horwitz, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03597698: Ill-health Related Job Loss
Official title: Ill-health Related Jobloss
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Job Loss Noticed by the Occupational Physicians
Keywords: job loss
unfit for a job
Lead sponsor: University Hospital, Montpellier
Sponsor class: OTHER
Collaborators: name: Université Montpellier
name: Occupational Health Center, Montpellier, France
First posted: 2018-07-24
Enrollment: 50000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: all the workers followed up in an occupational health center of Montpellier

Brief summary: The current study aimed to estimate the one-year incidence of unfitness for the job in an occupational health service, and to describe their aetiology and the characteristics of the unfit employees


Eligibility criteria: Inclusion Criteria:

- to be followed-up in the occupational health center

Exclusion criteria:

- civil servants

Primary outcomes:
measure: number of job loss
timeFrame: 1 day
Secondary outcomes:
measure: highlight trades or sectors associated with increased risk of medical incapacity
timeFrame: 1 day
Other outcomes:
Locations:
city: Montpellier
country: France
facility: Uhmontpellier
Study officials:
affiliation: University Hospital, Montpellier
name: Francois Xavier LESAGE, MD, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01141998: Vitamin D Substitution for Patients With Chronic Pancreatitis and Malabsorption
Official title: Vitamin D Substitution for Patients With Chronic Pancreatitis and Malabsorption
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Pancreatitis
Malabsorption Syndromes
Lead sponsor: Hvidovre University Hospital
Sponsor class: OTHER
First posted: 2010-06-11
Enrollment: 27
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Purpose:

The overall objective of this study is to learn more about the disease chronic pancreatitis and thus contribute to better treatments. The investigators will gain this by studying the effects of vitamin D in the body immune system and bones. The investigators will also study the uptake of vitamin D through the intestine compared with the amount of vitamin D obtained through exposure to UVB rays.

The investigators have set a series of questions which the investigators want to answer with this experiment:

Do patients with chronic pancreatitis have reduced absorption of vitamin D from the gut?

* Have the two treatment methods with vitamin D, UV radiation and tablets, the same success rate?
* Does the distribution of the white blood cells change when the vitamin D level increases and does it depend on whether the patient have UVB radiation or tablet with vitamin D?
* Will patients require reduced amounts of painkillers when vitamin D level increases?
* Does vitamin D have influence on blood sugar and thus the risk of diabetes or worsening of this?
* Could vitamin D affect the blood content of inflammation markers?
* Does the patient feel better when he takes vitamin D?
* Does bone strength increase when the patients receive grants of vitamin D?


Eligibility criteria: Inclusion Criteria:

* Chronic pancreatitis
* Malabsorption
* Age min. 18 y.
* 25-hydroxyvitamin D less than 75 nmol/l
* Body mass index \< 30
* Consent

Exclusion Criteria:

* Acute pancreatitis
* Cirrhosis
* Ionized calcium \> 1.35 mmol/l
* Heart disease
* Former resection of gastro-intestinal tract.
* Pregnancy
* Pancreatic malignant disease
* History of skin cancer
* Other than skin cancer less then 5 y prior to inclusion in study
* Chronic kidney disease
* Type I diabetes
* Hemoglobin \< 5.0 mmol/l
* Participating in other studies
* Not suitable for inclusion

Primary outcomes:
measure: 25-hydroxyvitamin D
timeFrame: Week 0, 2, 6, 10, 14, 20, 30, 40, 52
Secondary outcomes:
measure: T-lymphocytes subsets.
timeFrame: Week 0, 10
measure: Ionized calcium
timeFrame: week 0, 2, 6, 10, 14, 20, 30, 40, 52
measure: Parathyroid hormone
timeFrame: Week 0, 2, 6, 10, 14, 20, 30, 40, 52
measure: QoL score
timeFrame: Week 0, 10
Other outcomes:
Locations:
city: Hvidovre
country: Denmark
facility: Hvidovre Hospital
Study officials:
affiliation: Dept. of osteoporosis, Hvidovre Hospital
name: Jens-Erik B Jensen, Ph.d.
role: STUDY_DIRECTOR
References:
Clinical trial NCT05633498: Self-help Book for Shift Work Related Problems
Official title: The Effect of a Self-help Book for Shift Work Related Problems - a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Shift-work Disorder
Lead sponsor: University of Bergen
Sponsor class: OTHER
First posted: 2022-12-01
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim is to assess whether a self-help book for coping with shift work will reduce complaints in relation to shift work.

Detailed description: This study is a randomized controlled trial evaluating the effect of a self-help book for shift work related problems compared to the effect of sleep hygiene advice in participants with shift work disorder. 300 participants will be randomized to receive either the book or the sleep hygiene advice. Participants complete questionnaires about sleep, sleepiness and health at baseline and after 6 months after receiving the written material. The main aims are to assess whether the book is more effective to reduce sleep and sleepiness problems in relation to shift work, and to reduce the prevalence of shift work disorder, to increase knowledge about sleep and circadian rhythms, improve health, and reduce turnover intention.

Eligibility criteria: Inclusion Criteria:

* Symptoms suggesting shift work disorder
* Health care worker

Exclusion Criteria:

* Below 18 years

Primary outcomes:
measure: Sleep problems
timeFrame: 6 months
measure: Sleepiness problems
timeFrame: 6 months
Secondary outcomes:
measure: Shift work disorder
timeFrame: 6 months
measure: Knowledge about shift work and health
timeFrame: 6 months
measure: Sick leave
timeFrame: 6 months
measure: Turnover intention
timeFrame: 6 months
Other outcomes:
Locations:
city: Bergen
country: Norway
facility: University of Bergen
state: Hordaland
Study officials:
References: